The relevance of intestinal dysbiosis in liver transplant candidates

Transplant Infectious Disease

Volumn 17, Issue 2, 2015, Pages 174-184

  Grat, M ^a   Holowko W ^a   Wronka, K M ^a   Grat, K ^a   Lewandowski, Z ^a   Kosinska I ^a   Krasnodebski, M ^a   Wasilewicz, M ^a   Galecka, M ^b   Szachta, P ^b   Zborowska, H ^a   Patkowski, W ^a   Krawczyk, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Institute of Microecology   (Poland)

Author keywords

Bifidobacterium; Enterococcus; Gut microbiota; Liver cirrhosis; Liver transplantation; Model for End stage Liver Disease

Indexed keywords

BILIRUBIN; CREATININE; HYDROGEN PEROXIDE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BIFIDOBACTERIUM; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSBIOSIS; ENTEROCOCCUS; ESCHERICHIA COLI; FECES MICROFLORA; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTESTINE FLORA; LACTOBACILLUS; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MALE; MICROBIAL COMMUNITY; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; YEAST; BLOOD; COHORT ANALYSIS; END STAGE LIVER DISEASE; FECES; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AGED; BIFIDOBACTERIUM; BILIRUBIN; COHORT STUDIES; CREATININE; DYSBIOSIS; END STAGE LIVER DISEASE; ENTEROCOCCUS; ESCHERICHIA COLI; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTERNATIONAL NORMALIZED RATIO; LACTOBACILLUS; LINEAR MODELS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YEASTS; YOUNG ADULT;

EID: 84925405814     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12352     Document Type: Article

References (36)

1. Mondot S, de Wouters T, Doré J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis 2013; 31: 278-285.
2. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249.
3. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267.
4. Festi D, Schiumerini R, Birtolo C, et al. Gut microbiota and its pathophysiology in disease paradigms. Dig Dis 2011; 29: 518-524.
5. Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes 2012; 2012: 879151.
6. Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 2012; 18: 337-346.
7. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014; 59: 328-339.
8. Zorzi D, Rastellini C, Freeman DH, Elias G, Duchini A, Cicalese L. Increase in mortality rate of liver transplant candidates residing in specific geographic areas: analysis of UNOS data. Am J Transplant 2012; 12: 2188-2197.
9. Barber K, Madden S, Allen J, Collett D, Neuberger J, Gimson A. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 2011; 92: 469-476.
10. Györi GP, Silberhumer GR, Zehetmayer S, et al. Dynamic changes in MELD score not only predict survival on the waiting list but also overall survival after liver transplantation. Transpl Int 2012; 25: 935-940.
11. Grat M, Kornasiewicz O, Grat K, et al. Short and long-term outcomes after primary liver transplantation in elderly patients. Pol Przegl Chir 2013; 85: 581-588.
12. Lata J, Novotný I, Príbramská V, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19: 1111-1113.
13. Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33: 31-39.
14. Vera A, Contreras F, Guevara F. Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundación Santa Fe de Bogotá, Colombia. Transpl Infect Dis 2011; 13: 608-615.
15. Kim YJ, Kim SI, Wie SH, et al. Infectious complications in living-donor liver transplant recipients: a 9-year single-center experience. Transpl Infect Dis 2008; 10: 316-324.
16. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg 2011; 201: 498-502.
17. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol 2011; 61: 693-703.
18. Liu J, Wu D, Ahmed A, et al. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Curr Microbiol 2012; 65: 7-13.
19. Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949-955.
20. Wiegand RE. Performance of using multiple stepwise algorithms for variable selection. Stat Med 2010; 29: 1647-1659.
21. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
22. Wong VW, Tse CH, Lam TT, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis - a longitudinal study. PLoS One 2013; 8: e62885.
23. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5): 940-947.
24. Malaguarnera M, Gargante MP, Malaguarnera G, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010; 22: 199-206.
25. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995; 23: 39-46.
26. Wu ZW, Ling ZX, Lu HF, et al. Changes of gut bacteria and immune parameters in liver transplant recipients. Hepatobiliary Pancreat Dis Int 2012; 11: 40-50.
27. Moratalla A, Gómez-Hurtado I, Santacruz A, et al. Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis. Liver Int 2014; 34: (6): 850-858.
28. Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol 2013; 13: 175.
29. Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998; 65: 439-442.
30. Bucheli E, Kralidis G, Boggian K, et al.; and the Swiss Transplant Cohort Study. Impact of enterococcal colonization and infection in solid organ transplantation recipients from the Swiss Transplant Cohort Study. Transpl Infect Dis 2014; 16: 26-36.
31. Atassi F, Servin AL. Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosis-associated pathogens. FEMS Microbiol Lett 2010; 304: 29-38.
32. Strus M, Janczyk A, Gonet-Surowka A, et al. Effect of hydrogen peroxide of bacterial origin on apoptosis and necrosis of gut mucosa epithelial cells as a possible pathomechanism of inflammatory bowel disease and cancer. J Physiol Pharmacol 2009; 60 (Suppl 6): 55-60.
33. Strus M, Gosiewski T, Fyderek K, et al. A role of hydrogen peroxide producing commensal bacteria present in colon of adolescents with inflammatory bowel disease in perpetuation of the inflammatory process. J Physiol Pharmacol 2009; 60 (Suppl 6): 49-54.
34. Golińska E, Tomusiak A, Gosiewski T, et al. Virulence factors of Enterococcus strains isolated from patients with inflammatory bowel disease. World J Gastroenterol 2013; 19: 3562-3572.
35. Garcia-Mazcorro JF, Suchodolski JS, Jones KR, et al. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiol Ecol 2012; 80: 624-636.
36. Merli M, Lucidi C, Di Gregorio V, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int 2015; 35: 362-369.